Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Sarcoma 1Melanoma 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Head and Neck Neoplasms 1

Interventions

Doxorubicin 69Radiotherapy 50Ifosfamide 48Gemcitabine 43Cyclophosphamide 36pazopanib 29Filgrastim 28pembrolizumab 26Docetaxel 26Nivolumab 23Etoposide 21Cisplatin 21Surgical Procedures, Operative 20Trabectedin 19Blood Specimen Collection 19Carboplatin 15Radiation 14Magnetic Resonance Spectroscopy 14Vincristine 13Bevacizumab 13Temozolomide 12Peripheral Blood Stem Cell Transplantation 12Ipilimumab 12liposomal doxorubicin 11apatinib 11anlotinib 11Radiosurgery 11Melphalan 11Surveys and Questionnaires 10Sirolimus 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sarcoma × Nanoparticles × Clear all
NCT05264974 2026-05-27

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

University of Florida

Phase 1 Suspended
18 enrolled
DermatologicSarcoma

Melanoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡